OBR Daily Commentary

forumImage

Trump Proposes Reduction Of Drug Costs Under Medicare

(ABCNews.com) Feb 9, 2018 - President Donald Trump will propose lowering prescription drug costs for Medicare beneficiaries by allowing them to share in rebates that drug companies pay to insurers and middlemen, an administration official said.

Read Article arrow

Dean Gesme, MD (Posted: February 11, 2018)

quotesIncreasing transparency in drug pricing and total costs of care attributable to drugs can only serve to foster greater intelligence and insight into the use of pharmaceuticals in the US.quotes

Add Comment 1 Comment
forumImage

German Watchdog Calls For Direct Comparison Of Cancer Immunotherapies

(Reuters) Jan 15, 2018 - Germany’s drug assessment body has criticized a lack of data directly comparing drugs in a promising new class of cancer immunotherapy, saying physicians could be overwhelmed or misled by the available information.

Read Article arrow

Dean Gesme, MD (Posted: January 16, 2018)

quotesThis call for head to head trials of checkpoint inhibitors is spot on. These trials may be necessary in order to avoid a “commoditization” of this class of drugs by payer/provider interests seeking to reduce excessive treatment costs with immunotherapies given the lack of documented clinically significant differences in efficacy and safety within this class.quotes

Add Comment 2 Comment
forumImage

Oncologists, Beware: Expensive Liquid Biopsy Tests Produce Conflicting Results

(Forbes) Dec 15, 2017 - A new study shows that two commercially available liquid biopsy tests for cancer produce strikingly different results when analyzing exactly the same samples. Should oncologists and patients trust them?

Read Article arrow

Dean Gesme, MD (Posted: December 20, 2017)

quotesTumor heterogeneity is well described but the variability in these NextGen liquid biopsy results seriously calls into question how and when these test results inform best clinical practices for these patients!quotes

Add Comment 1 Comment

Meet the Editorial Board

Community Oncology
member photo
Dean Gesme, MD

FACP FACPE FASCO President, Minnesota Oncology...

Breast Cancer
member photo
Debu Tripathy, MD

Professor and Chair, Department of Breast Medical Oncol...

Lung Cancer
member photo
H. Jack West, MD

Medical Director, Thoracic Oncology Program, Swedish Ca...

Gastrointestinal Cancers
member photo
Howard S. Hochster, MD

Distinguished Professor of Medicine, Rutgers Robert Woo...

Radiation Oncology
member photo
Howard Sandler, MD, MS, FASTRO

Ronald H. Bloom Chair in Cancer Therapeutics
Pr...

Community Oncology
member photo
Jeff Patton, M.D.

CEO Tennessee Oncology...

Precision Medicine Section Editor
member photo
Jennifer Levin Carter, MD, MPH

Chief Medical Officer and Founder, N-of-One...

Financial Sector
member photo
Michael G. King Jr.

Managing Director and Senior Biotechnology Analyst...

Gastrointestinal Cancers
member photo
Richard Goldberg, MD

Director WVU Cancer Institute Director of Cancer Signa...

Editor-In-Chief
member photo
Robert A. Figlin, MD., FACP

Professor and Director, Division of Hematology Oncology...

Health Policy
member photo
Ted Okon

Executive Director Community Oncology Alliance...

Community Oncology
member photo
Thomas Marsland, MD

Vice President Integrated Community Oncology Network ...

Community Oncology
member photo
William Harwin MD

Florida Cancer Specialists President and Managing Part...

Health Policy
member photo
William McGivney, PhD

National Health Policy Expert...

Payer
member photo
Winston Wong, PharmD

President, W-Squared Group...